IgPro10

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

31 competitors in Pediatric

#DrugCompanyPhaseTrials

1

Oxycontin

PProtega

Approved

22

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

13

Siliq

BBausch Health Americas, Inc.

Approved

14

Venclexta

AbbVie

Phase 3

15

Blincyto

Amgen

Phase 3

16

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

17

Luye

Ascentage Pharma Group Inc.

Phase 3

18

Homoharringtonine

Ascentage Pharma Group Inc.

Phase 3

19

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

110

Fycompa

CCatalyst Biosciences

Phase 2

1Show 14 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Systemic Sclerosis2 trials

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

Withdrawn·CSL Behring·Phase 2·NCT04138485

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

Completed·CSL Behring·Phase 2·NCT04137224·27 enrolled

Thrombocytopenic Purpura1 trial

A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)

Completed·CSL Behring·Phase 4·NCT01390649·57 enrolled

Pediatric1 trial

Two Dose Levels of Privigen in Pediatric CIDP

Recruiting·CSL Behring·Phase 4·NCT03684018·30 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Completed·CSL Behring·Phase 3·NCT01545076·208 enrolled

Details

Drug Info

Related News